# EUFEPS ANNUAL MEETING 2019 6-8 MARCH 2019 FRANKFURT AM MAIN, GERMANY

# SUPPORTING SOCIETIES

























# **CONFIRMED SPONSORS**

















	Wednesday, March 6 <sup>th</sup> , 2019	
Pre-Symposium of the EUFEPS Network "History of Pharmacy": Pharmacy in Germany Venue: Lecture hall H4		
10:00 <b>–</b> 10:15	Axel Helmstädter, Frankfurt, Germany Welcome from the head of the network History of Pharmacy	
10:15 <b>–</b> 11:00	Axel Helmstädter, Frankfurt, Germany Development of the German Pharmacy System	
11:00 <b>–</b> 11:45	Sabine Bernschneider-Reif, Darmstadt, Germany 350 years of Merck, the oldest pharmaceutical company in the world	
11:45 <b>–</b> 12:15	Coffee Break	
12:15 <b>–</b> 13:00	Stefan Wulle, Braunschweig, Germany Pharmaceutical library services in the digital age	

	Wednesday, March 6 <sup>th</sup> , 2019 Main Symposium (Congress language English)
13:00 – 13:30	Opening of the EUFEPS ANNUAL CONFERENCE 2019 (lecture hall H3)  Personalized Medicines, Targeted Therapies, Precision Drug Delivery  Simone Fulda (Vice President Goethe University Frankfurt)  Jochen Maas (Vice President House of Pharma)  Dieter Steinhilber (President EUFEPS)
13:30 <b>–</b> 14:00	Plenary lecture 1, Daniel Müller (Canada), Towards implementation of pharmacogenetics in psychiatry P.1
14:00 <b>–</b> 14:30	Plenary lecture 2, Juan José Lasarte (Spain), Awakening the immune system to fight cancer P.2
14:30 <b>–</b> 15:00	Plenary lecture 3, Jean-Christophe Leroux (Switzerland), Bad reasons for publishing research findings and their negative impact on data reliability  P.3
15:00 <b>–</b> 15:30	Coffee break

# SHORT TALKS (parallel sessions I)

15:30 <b>-</b> 17:00	SL1 (lecture hall H4)	SL2 (lecture hall H3)
	Drug Targets	Drug formulation
	Oncology Chairs: Stefan Knapp, Stefan Laufer	EUFEPS Networks on NanoMedicine and BABP with NBCD Working Group NBCDs, Nanomedicines and Nanosimilars Chairs: Erem Bilensoy, Gerrit Borchard, Henning Blume
	15:30 SL.01 Christa Müller: Development of tools and drugs targeting purine-binding membrane proteins for cancer Immunotherapy	15:30 SL.06 Gerrit Borchard: Bridging the nano-gap: Critical quality attributes for non-biological complex drugs
	15:50 SL.02 Manfred Jung: Chemical epigenetics - inhibitors of reversible lysine acetylation and methylation	15:50 SL.07 Susanne Bremer: Mapping nanomedicine terminology and the regulatory landscape
	16:10 SL.03 Lars Zender: Translating liver cancer biology: From functional target discovery to academic drug discovery and development	16:10 SL.08 Erem Bilensoy: Global -omics approach to develop nanomedicines
	16:30 SL.04 Rolf Marschalek: Investigating HDACi and dnTaspase1 for the treatment of (4;11) leukemic cells	16:30 SL.09 Felix Schacher: Polyether-based block copolymers as versatile toolbox in nanomedicine: crosslinking, charge control and cargo-carrier interactions
	16:45 SL.05  Daniel Merk:  A designed dual modulator of farnesoid X receptor and soluble epoxide hydrolase with synergistic efficacy in non-alcoholic steatohepatitis	16:45 SL.10 Diego Romano Perinelli: New insights regarding the chemical-physical characterization of liposomal formulations: the case of Doxil®

Chairs: Korbinian Löbman			n/Märit Johansson	
17:00 – 18:00	17:00 Eren Demirpolat: The relationship between voriconazo effects, plasma concentration and polymorphisms in haematological malignancy patients	FP.01 le side	17:30 Selin Yüksel: Adjuvant activity of chitosan-porins syon murine macrophages	FP.07 ystems
	17:05 Ozlem Coban: pH-dependent release of niclosamide Eudragit nanofibers for colon targetin formulation development and in vitro characterization studies		17:35 Hazal Ezgi Gültekin: Evaluation of the effect of physical st properties on the drug release profile tablets manufactured by fused deposit modelling-3D printing	of the
	17:10 Hristos Glavinas: Investigations of the mechanism beharapid absorption of nano-amorphous abiraterone acetate	FP.03 ind the	17:40 Vildan Yozgatli: Tetrahydrozoline hydrochloride loade microemulsions: Development, characterization and in vitro - in vivo evaluation	FP.09 ed ocular
	17:15 Anna Muriel Jacinto: Preformulation and formulation studie alcoholic extract of Punica granatum (Lythraceae) exocarp as antimicrobia ointment	L.	17:45 Aysee Esra Karaday: Cytotoxic effects and anti-oxidant act Opuntia ficus-indica (L.) Mill. fruit exti various cancer cell lines	
	17:20 Sila Gulbag: Cyclosporine A nanosuspension proc by wet media milling method: Develop and characterization		17:50 Robert Wawrzinek: A targeted delivery system for Lange cells	FP.11 rhans

FP.06

Flash presentations (lecture hall H3)

18:00 **–** 21:30

17:25

Poster Session I and Welcome Reception

Ayse Nur Oktay:
Flurbiprofen nanosuspension based gel systems: Wet milling assisted production of nanosuspensions for dermal application

	Thursday, March 7 <sup>th</sup> , 2019	
Plenary lectures (lecture hall H3) Chair: Erem Bilensoy.		
09:00 <b>–</b> 09:30	Plenary lecture 4, Ravi Kumar (USA), Next generation nanosystems in drug delivery: It's all about delivery  P.4	
09:30 <b>–</b> 10:00	Plenary lecture 5, Frank Buchholz (Germany), Programmable nucleases and designer recombinases for genome surgery  P.5	
10:00 <b>–</b> 10:30	Coffee break	

### **SHORT TALKS (parallel sessions II)**

10:30 <b>–</b> 12:00	SHORT TALKS (paral	SL4 (lecture hall H3)
	Drug Targets	Drug formulation
	Biomarkers for personalized medicines or: Omics technologies Chairs: Theo Dingermann, Anna Eichhorn	EUFEPS Networks on NanoMedicine and BABP with NBCD Working Group NBCDs, Nanomedicines and Nanosimilars Chairs: Erem Bilensoy, Gerrit Borchard, Henning Blume
	10:30 SL.11 Daniel Müller: From basepairs to bed: Clinical application of pharmacogenetics to optimize psychiatric medication treatment	10:30 SL.16 Peter Wick: Influencing factors on nanomedicines efficacy and safety: An iron-carbohydrate complex perspective
	10:50 SL.12  Martina Hahn:  Experiences with the use of Pgx testing in psychiatry	10:50 SL.17 Patrick Boisseau: Defining critical attributes of nanomedicines: The contribution of the European Nanomedicine Characterisation Laboratory
	11:10 SL.13  Daniela Steinberger:  Overcoming of clinical obstacles with  "Ubiquitous Pharmacogenomics" (U-PGx):  The time for implementation is now.	11:10 SL.18 Ildiko Csoka Potentials and threats of the colloidal systems as carriers for peptide drugs
	11:30 SL.15 Nancy Hakooz: Differences in UGT1A1 and UGT1A7 Polymorphisms between Circassian, Chechen and Jordanian-Arab populations	11:30 SL.19 Tiziana Di Francesco: Is nano just a formulation? The case of intravenous iron-based nano-colloidal products
	11:50 Discussion	11:45 Podium discussion Henning Blume (moderator) Rogério Gaspar
12:00 <b>–</b> 13:30	Lunch break	

# SHORT TALKS (parallel sessions III)

13:30 -	SL5 (lecture hall H4)	SL6 (lecture hall H3)
15:00	Drug Targets	Drug formulation
	Personalized medicine outside of	Targeted Drug Delivery and Age-

	Oncology Chairs: Jochen Maas, NN	<b>appropriate formulations</b> Chairs: Niklas Sandler, Maria Blanco-Prieto
	13:30 SL.20 Hartmut Ruetten: Precision Medicine in the management of diabetes	13:30 SL.24  Jessica Rosenholm:  Mesoporous silica nanoparticles as drug reservoirs for enhancing the dissolution of poorly soluble drugs in dosage form design
	13:55 SL.21 Birgit Aßmus: Personalized medicine in cardiology – from genes to daily life	13:50 SL.25 Andreas Bernkop-Schnürch: Mucoadhesive polymers in targeted mucosal drug delivery and therapy
	14:20 SL.22 Angel Cedazo-Minguez: The need of personalized medicine in neurodegenerative disorders	14:10 SL.26 Catherine Tuleu: Insight into paediatric formulations
	14:45 SL.23  Dunja Urbancic: Insights into the biological function of thiopurine S-methyltransferase: the involvement in selenium metabolism	14:30 SL.27 Silvia Pescina: Peptides and proteins: advantages and hurdles in ocular delivery
		14:45 SL.28 Ferenc Fenyvesi: Pharmacokinetics and tissue distribution of PET radiotracer labelled hydroxypropyl-beta- cyclodextrin
15:00 <b>–</b> 15:30	Coffee break	

# SHORT TALKS (parallel sessions IV)

15:30 – 17:00	SL7 (lecture hall H4)	SL8 (lecture hall H3)
		Drug formulation/ PAT
	EUFEPS Network Pharmacogenetics Research and Implementation (EPRIN) Chairs: Ana Alfirevic, Ann Daly	EUFEPS Network QbDPAT Chairs: Jukka Rantanen, Maike Windbergs
	15:30 SL.29 Ann Daly: Pharmacogenomics of drug-induced liver injury	15:30 SL.34 Johannes Khinast: Digital design of products and processes in the context of advanced pharmaceutical manufacturing
	15:50 SL.30 Anke-Hilse Maitland-van der Zee: Precision Medicine in respiratory disease, are we beyond fiction?	15:50 SL.35 Hélder Santos: Microfluidics fabrication of nanomedicines

16:10 S Ingolf Cascorbi: Pharmacogenetics of immune-modula Therapy	L.31 ating	16:10 Fridolin Okkels: Process rheology of semisolid products	SL.36
16:30 S Eugenia Hoffmann: Advanced bioanalysis for a better understanding of immunogenicity	L.32	16:30 Heike Bunjes: Drug loading capacity of lipid nanopartion	SL.37
16:45 S Meike Saul: miR-574-5p as RNA decoy for CUGB stimulates human lung tumor growth in mPGES-1 induction		16:45 Joao Lopes: A risk assessment based pharmaceutic materials sampling methodology	SL.38 al raw-

# SHORT TALKS (parallel sessions V)

17:00 - 18:30	SL9 (lecture hall H4)	SL10 (lecture hall H3)
	EUFEPS Network Veterinary Medicines Chairs: Ivo Schmerold, Aletta Kraneveld	EUFEPS Network Dermatopharmacy Chairs: Barbara Schug, Betsy Hughes- Formella
	17:00 SL.39 Ronette Gehring: Personalized Medicines: All creatures great and small - what do personalised medicines mean for veterinarians?	17:00 SL.43  Marc Brown: In vitro performance testing in de-risking topical formulation development
	17:20 SL.40 Henrik Rönnberg: Targeted Therapies: Cancer therapy in companion animals – a comparative research approach	17:30 SL.44 Frank Sinner: In vivo skin PK testing for new and generic topical dermatological drug development
	17:40 SL.41 Şevda Senel: Precision drug delivery to animals: Formulation challenges	
	18:00 SL.42 Maria Manuela Gaspar: Nanoformulated hybrid molecules with high in vitro and in vivo potential against melanoma	18:00 SL.45 Janet König: The new European Draft Guideline on equivalence of topical products
	18:15 Block discussion	
19:30 <b>–</b> 24:00	Conference Dinner	

_	Friday, March 8	Rth 2010	
Plenary lectures (lecture hall H3)			
	Chair: Jochen Klein.		
08:30 <b>–</b> 09:00	Plenary lecture 6, Kathy Giacomini (USA), Global consortia: Empowering pharmacogenomic studies P.		
09:00 <b>–</b> 09:30	Plenary lecture 7, Maria José Alonso (Spai formulation of proteins	n), Why to use nanotechnology for the P.7	
09:30 <b>–</b> 10:00	Plenary lecture 8, Ugur Sahin (Germany), /	ndividualized cancer immunotherapy P.8	
10:00 <b>–</b> 10:30	Coffee break		
	SHORT TALKS (paralle	el sessions VI)	
10:30 -	SL11 (lecture hall H4)	SL12 (lecture hall H3)	
12:00	Drug Targets	Drug formulation	
	<b>EUFEPS Network Systems Pharmacology</b>		
	Chairs: Achim Schmidtko, Coen van Hasselt	<u> </u>	
	10:30 SL.46 Piet van der Graaf (Douwe Breimer	10:30 SL.51 Ulrike Alexiev:	
	lecture):	Fluorescence lifetime imaging microscopy as	
	From precision medicine to accurate therapy using QSP	analytical tool for drug delivery systems and drug delivery	
	10:50 SL.47	10:50 SL.52	
	Iñaki Troconiz:	Axel Zeitler:	
	Systems pharmacology models to understand the contribution of the immune response to treatment effects	Fast, non-destructive terahertz dissolution assay for immediate release tablets	
	11:10 SL.48	11:10 SL.53	
	Max von Kleist: A quantitative systems pharmacology	Jesper Østergaard: UV-Vis based dissolution imaging for	
	approach to evaluating the potential of antivirals for repurposing in HIV prophylaxis	formulation development	
	11:30 SL.49	11:30 SL.54	
	Guido Zaman:	Muge Kilicaslan:	
	Identification of predictive drug response biomarkers for all kinase inhibitors approved for clinical use by combined cellular and biochemical profiling	Non-destructive 3D imaging and quantitative analysis of clindamycin phosphate loaded PLGA nanoparticles by using nano-CT	
	11:45 SL.50	11:45 SL.55	
	Jonas Petersen:	Ayse Ercan:	
	Distinct functions of NO-GC isoforms in the processing of chronic pain	A metabolomic study to investigate the effect of folate conjugated nanoparticles on triple negative breast cancer cells	
12:00 <b>–</b> 13:00	Lunch break		
	SHORT TALKS (paralle	el sessions VII)	
13:00 -	SL13 (lecture hall H4)	SL14 (lecture hall H3)	
14:30	<b>Novel drugs</b> Chairs: Robert Fürst, Anders Karlén (EFMC)	Regulatory Science /Drug Delivery Chairs: Rogério Gaspar, Eva Szökö	
	13:00 SL.56	13:00 SL.60	
	<b>Dennis Schade:</b> Opening the 'Druggable Space' using	Paola Minghetti: The regulatory approach for old active	
	phenotypic stem cell screening platforms	ingredients in complex delivery systems	
	13:30 SL.57	13:20 SL.61	
	Brinton Seashore-Ludlow:	Beat Flühmann:	
	HTS-compatible target engagement assays	Current practice of EU regulators approving	

	for drug discovery and beyond	nanosimilars and subsequent need for education of HCP
	14:00 SL.58 Paula Perez-Pardo: Positive effects of tryptophan-2,3- dioxygenase inhibitors on motor function, cognition and gastrointestinal symptoms in a mouse model of Parkinson's disease	13:40 SL.62 Sumit Arora: Modeling in vitro skin permeation experiments to mechanistically understand in vivo dermal absorption: Application of in vitro-in vivo extrapolation (IVIVE) and physiological based pharmacokinetic (PBPK) modeling using testosterone as model drug
	14:15 SL.59 Eugen Proschak: Simultaneous treatment of hyperglycemia, hypertension, and dyslipidemia in metabolic syndrome using a designed multitarget ligand	14:00 SL.63 Panos Macheras: Drug delivery using nature's emulsion: milk
		14:15 SL.64 Ebru Basaran: Voriconazole incorporated inclusion complexes for improved ocular delivery
14:30 <b>–</b> 15:00	Closing ceremony (lecture hall H3)	